BARD1 and prostate carcinoma: Taken together, available data from non-prostate cancer contexts suggest that alterations in genes such as PALB2 or BARD1 can impact HR function and modulate PARP inhibitor sensitivity; however, each of these genes is altered too infrequently in mCRPC to assess the gene-level impact on PARP inhibitor sensitivity in a prospective clinical trial.